Prof. PeptideProf. Peptide
Guide

How is BPC-157 dosed?

BPC-157 (Body Protection Compound-157) is a lab-made peptide of 15 amino acids, studied for tendon, ligament, muscle and gut recovery. No trial has set a dose and it is not FDA-approved. This page reports the doses its human studies gave, the registered trials, and the range clinics publish, each attributed to its source.

Topic: The doses BPC-157 has been given in people, study by study, and the doses clinics publish

Audience: Anyone comparing a BPC-157 dose figure against what has been studied

Reading time: 8–10 minutes

Has any trial set a BPC-157 dose?

No trial has set a BPC-157 dose. FDA’s July 2026 briefing document states there is no approved product containing it in any country and no USP or NF monograph for it, so no label gives a dose. The doses on record come from three small uncontrolled pilots, one 2005 enema study, and the protocols clinics publish, which are not drawn from any of them.

FDA’s search of PubMed and Embase found five clinical studies that used BPC-157, and FDA found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use. The BPC-157 profile covers its reported uses, how clinicians explain its mechanism, and side effects; this guide sets the study doses and clinic doses side by side.

How do clinics dose BPC-157?

Clinics commonly prescribe BPC-157 at 250 to 500 mcg a day by subcutaneous injection, once or twice daily, in courses of 4 to 8 weeks followed by a break; the range clinics publish is 200 to 1,000 mcg (1 mg) a day over 2 to 16 weeks. These are clinic practice, not trial doses: no clinic ties its figure to a study.

Of 69 clinic pages read for this guide, 10 clinics publish an injection figure; the other pages leave the dose to the prescriber or give only a vial size. Six of the 10 give 250 to 500 mcg a day; the table below lists them with their schedules, and Defy Medical's figure is from its BPC-157 + TB-500 stack page.

Clinics that offer oral BPC-157 most often supply 500 mcg capsules taken once daily, in courses of up to 12 weeks; a compounding pharmacy also lists a 1,000 mcg (1 mg) strength. Reconstitution arithmetic for a vial is on the peptide dosage calculator.

BPC-157 doses as clinics publish them (pages read November 4, 2026). The clinics listed are representative of the 69 clinic pages read; most publish no dose figure. Clinic practice, not trial doses.
ClinicRouteDose as publishedSchedule and course
Dr Pat Taylor, MD (Live Vital)Subcutaneous or oral250–500 mcg a dayOne to two times daily, 3 to 5 times weekly; cycles of 4–12 weeks
VitalRxSubcutaneous injection250–500 mcg per injectionOnce or twice daily (acute); several times a week (maintenance)
Defy Medical (BPC-157 + TB-500 stack page)Subcutaneous injection, often near the injury250–500 mcg once dailyCycles of 4–8 weeks, followed by a break
Dr. Rogers CentersNot stated in the line quoted250–500 mcg once or twice daily (200–1,000 mcg (1 mg) a day in most clinical settings, per the page)4–6 weeks
Optimize 360Subcutaneous injection200–600 mcg daily, with gradual titration8–12 weeks (extended to 16 if desired)
Pramah / The HavenIntramuscular injection300 mcgDaily in the evening, 30-day protocol
Perfect BInjection near the target injury site250–500 mcg once or twice daily4–6 weeks
Institute for Healthy Aging (AMT Care)Subcutaneous injection200–300 mcg a day in a single injection; up to 800 mcg split in 2 doses, per the pageDaily for up to 4 weeks
Beyond Stem CellsSubcutaneous injection250–500 mcg a day4–12 weeks
Yunique MedicalInjection200–500 mcg a day to start (250–1,000 mcg (1 mg) a day, per the page)Most cycles 2–4 weeks
Wittmer Rejuvenation ClinicOral capsuleOne 500 mcg capsule daily12 weeks, then a 4–8 week break
VitalRxOral capsule500 mcg capsules (20-count)Not stated
Yunique MedicalOral capsuleUp to 500 mcg, as the page writes it, "/day/2 times a day"Not stated

What doses have human studies of BPC-157 used?

Human studies of BPC-157 have given single or short courses of large doses: 10,000 mcg (10 mg) (10 mg) into the bladder wall, up to 20,000 mcg (20 mg) by intravenous infusion, and 80,000 mcg (80 mg) a day as an enema for two weeks. All three published pilots come from one Florida group and none had a control group; the enema study survives only as a meeting abstract. None matches clinic dosing, which runs in micrograms daily for weeks.

Lee & Padgett 2021: knee pain (retrospective chart review)

Lee E, Padgett B. Altern Ther Health Med. 2021;27(4):8–13. PMID 34324435.

Design: A one-year retrospective chart review (2019 to 2020) at the Institute for Hormonal Balance in Orlando, Florida, of intra-articular BPC-157, alone or combined with thymosin beta-4 (TB4), for knee pain. Follow-up by phone survey, most patients 6 months to 1 year after the injection. The abstract states: "No specific tools were used to measure their improvement."

Participants: 17 patients in the study; 16 reached by phone. 12 received BPC-157 alone and 4 received BPC-157 with TB4.

Dose administered: Not stated in the abstract, which says only "intra-articular injection of the peptide BPC 157, alone or combined with TB4".

Result reported: 11 of 12 (91.6%) given BPC-157 alone reported significant improvement in knee pain; 14 of 16 (87.5%) overall had relief.

Adverse events reported: The abstract does not report on adverse events.

Lee, Walker & Ayadi 2024: interstitial cystitis (open-label pilot)

Lee E, Walker C, Ayadi B. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560.

Design: A pilot at a private clinic of BPC-157 "manufactured by a 503A compounding pharmacy", in women with moderate to severe interstitial cystitis who had not responded to pentosan polysulfate. No control group.

Participants: 12 women aged 39 to 76 (mean 58.3).

Dose administered: 10,000 mcg (10 mg) in total, injected around the area of bladder inflammation during a single cystoscopy.

Result reported: Complete resolution of symptoms after one treatment in 10 of 12; the other 2 rated their success at 80%.

Adverse events reported: "No one dropped out of the study, and no adverse events were reported."

Lee & Burgess 2025: intravenous safety pilot

Lee E, Burgess K. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143.

Design: An IRB-approved safety pilot at a private clinic in Florida: blood work and vital signs before and after each infusion. No efficacy endpoint and no control group.

Participants: 2 patients (a 58-year-old man and a 68-year-old woman), each of whom had received intravenous BPC-157 before.

Dose administered: Day 1: 10,000 mcg (10 mg) in 250 cc of normal saline over one hour. Day 2: 20,000 mcg (20 mg) in 250 cc over one hour.

Result reported: "No measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels." The authors conclude that future studies are needed to confirm the safety of intravenous BPC-157.

Adverse events reported: "Tolerated, with no side effects reported."

The ulcerative colitis study often described as a Phase II trial is, in FDA’s words, “a single meeting abstract” (Ruenzi et al., 2005): 53 people with mild to moderate ulcerative colitis were randomized to a BPC-157 enema of 80,000 mcg (80 mg) (80 mg) or placebo once daily for two weeks, and 46 completed it. Disease activity fell by 3.2 points with BPC-157 and 1.6 points with placebo; the confidence interval for the difference crossed zero, and FDA judged the data “inadequate to support the efficacy and safety of BPC-157 given as an enema.” BPC-157 was not detected in plasma in the enema studies.

Three trials are registered on ClinicalTrials.gov (read November 4, 2026). None has posted results:

NCT02637284: PCO-02 safety and pharmacokinetics trial (oral)

Status: Unknown status; last known status "Active, not recruiting"; last update posted December 22, 2015. Results were submitted on May 23, 2016 and never posted (the registry lists that submission as canceled).

Design: A Phase 1 pilot in healthy volunteers at Hospital Ángeles Tijuana, sponsored by PharmaCotherapia: oral PCO-02 tablets each containing 1,000 mcg (1 mg) of BPC-157, or placebo.

Arms: Single doses of 1, 3 or 6 tablets; then 3 tablets three times daily for 2 weeks. 42 participants estimated. Healthy volunteers, so not a trial in any disease.

NCT07437547: acute hamstring muscle strain (BPC-HAMSTR)

Status: Recruiting; started February 2, 2026; primary completion estimated February 14, 2027.

Design: A randomized, double-blind, placebo-controlled Phase 2 trial sponsored by Hudson Biotech at Peking University Shenzhen Hospital, China: subcutaneous injection once daily for 14 days.

Arms: 120 participants estimated. The dose is not stated on the registry page.

NCT07803250: recovery after rotator cuff repair (University of Arkansas)

Status: Not yet recruiting; start estimated January 1, 2027.

Design: A randomized, double-blind, placebo-controlled pilot: participants self-administer subcutaneous injections daily for 90 days after surgery.

Arms: 30 participants estimated (the summary says twenty). The dose is not stated.

What side effects have been reported at those doses?

Reported side effects of BPC-157 are few because the human record is small: the 2024 bladder pilot and 2025 intravenous pilot reported no adverse events in 12 and 2 patients, and the 2021 knee review’s abstract is silent on them. FDA’s adverse-event database search through December 4, 2025 retrieved three reports, all after injected BPC-157.

  • Nine days of redness and swelling around the injection site, in a 55-year-old woman also using compounded thymosin.
  • Shortness of breath leading to an emergency-room visit, in a 28-year-old man using subcutaneous BPC-157 acetate.
  • Diffuse skin and gum darkening after one week, recurring on rechallenge, in a 40-year-old woman using a BPC-157 and TB-500 product labeled for research purposes only; FDA notes that with two peptides in the product it is not possible to assess a relationship with BPC-157.

FDA states it lacks sufficient information to know whether compounded BPC-157 would cause harm, and is concerned about immunogenicity of injectable forms from aggregation and peptide-related impurities. Clinic pages that address safety state that no safe or maximum dose has been established and that higher amounts have not been shown to work better. The BPC-157 profile’s side-effects section lists the cautions clinics publish.

Is BPC-157 legal to compound?

BPC-157’s compounding status is unsettled. FDA’s list of bulk substances that may present significant safety risks (content current as of April 22, 2026) now shows BPC-157 among substances whose nominations to category 2 were withdrawn, and FDA staff’s July 2026 evaluation concluded that “a balancing of the criteria weighs against” adding BPC-157 to the 503A bulks list.

FDA’s stated reason for its earlier listing: compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization,” and FDA “lacks sufficient information to know whether the drug would cause harm when administered to humans.” FDA’s outsourcing-facility reports from January 2017 to June 2025 list no compounded products containing BPC-157.

The Pharmacy Compounding Advisory Committee met on July 23–24, 2026, and voted 8 to 6, with one abstention, in favor of adding BPC-157 to the 503A bulks list, ABC News reported that day; FDA has posted no minutes or vote results. A committee vote is advisory; FDA decides.

An HHS notice published in the Federal Register on October 30, 2026 (91 FR 68526) sets a draft Enforcement Discretion Policy under which HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A,” and states that it “is not binding on HHS or the public.” Which peptides Appendix A lists, and the routes it allows, are in the report on the HHS policy; the full status, question by question, is on Is BPC-157 legal?

FDA’s April 1, 2020 warning letter (594743) to Tailor Made Compounding LLC of Nicholasville, Kentucky, names BPC 157 among the substances the firm compounded, alongside GHRP-6, AOD 9604, GHK-Cu, Ipamorelin, Selank, Semax and CJC 1295.

Research-grade BPC-157, of the kind sold by the vendors Prof. Peptide tracks, is neither an approved product nor a 503A-compounded one. It is sold labeled for laboratory research use, not for human administration, and is not dispensed against a prescription.

FAQ

Is there an FDA-approved BPC-157 product?
No. FDA's July 2026 briefing document states there is no approved product containing BPC-157 in any country, no USP or NF monograph for it, and none in the European or Japanese pharmacopoeias. It is not a component of any FDA-approved drug, so no label sets a dose.
Has BPC-157 been tested in a controlled human trial?
Not one with posted or peer-reviewed results. FDA identified a 2005 meeting abstract of a 53-subject placebo-controlled enema study in ulcerative colitis and judged its data inadequate. NCT02637284 submitted results in 2016 that were never posted; NCT07437547 is recruiting and NCT07803250 has not started. The three published pilots are uncontrolled.
What doses did the human pilot studies use?
Lee, Walker and Ayadi 2024 injected 10,000 mcg (10 mg) around the inflamed bladder wall in one procedure in 12 women. Lee and Burgess 2025 infused 10,000 mcg (10 mg) on day 1 and 20,000 mcg (20 mg) on day 2 intravenously in 2 patients. The 2021 knee-pain review's abstract does not state its dose.
What dose do clinics commonly use for BPC-157?
Clinics commonly prescribe BPC-157 at 250 to 500 mcg a day by subcutaneous injection, once or twice daily, in courses of 4 to 8 weeks; the range clinics publish is 200 to 1,000 mcg (1 mg) a day and 2 to 16 weeks. Oral capsules are most often 500 mcg once daily. No clinic ties its dose to a trial.
What side effects of BPC-157 have been reported?
The 2024 bladder pilot and the 2025 intravenous pilot reported no adverse events in 12 and 2 patients. FDA's adverse-event database search through December 2025 found three reports, all after injection: injection-site redness and swelling, shortness of breath leading to an emergency visit, and skin and gum darkening with a BPC-157 and TB-500 product.
What is BPC-157's current FDA compounding status?
Unsettled. FDA's list of substances that may present significant safety risks now shows BPC-157 among nominations withdrawn from category 2. FDA staff's July 2026 evaluation concluded the criteria weigh against adding it to the 503A bulks list. An October 30, 2026 HHS notice sets a draft, non-binding enforcement discretion policy for the peptides in its Appendix A.

References

  1. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8–13. PMID 34324435 (abstract read November 4, 2026). https://pubmed.ncbi.nlm.nih.gov/34324435/
  2. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560. https://pubmed.ncbi.nlm.nih.gov/39325560/
  3. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143. https://pubmed.ncbi.nlm.nih.gov/40131143/
  4. ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial, NCT02637284 (PharmaCotherapia d.o.o.); study page and results tab read November 4, 2026. https://clinicaltrials.gov/study/NCT02637284
  5. ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR), NCT07437547 (Hudson Biotech); read November 4, 2026. https://clinicaltrials.gov/study/NCT07437547
  6. ClinicalTrials.gov. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery, NCT07803250 (University of Arkansas); read November 4, 2026. https://clinicaltrials.gov/study/NCT07803250
  7. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026: BPC-157 related bulk drug substances (cited for approval and monograph status, the Ruenzi 2005 enema abstract, human pharmacokinetics, outsourcing-facility reports, FAERS reports and FDA’s evaluation); read November 4, 2026. https://www.fda.gov/media/193343/download
  8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (content current as of April 22, 2026); read November 4, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  9. U.S. Food and Drug Administration. Warning Letter: Tailor Made Compounding LLC, reference 594743, April 1, 2020. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020
  10. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, FR Doc. 2026-22192, 91 FR 68526 (October 30, 2026); text read November 4, 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  11. Defy Medical. What is the Wolverine peptide stack? Cited for its published BPC-157 dose (250 to 500 mcg once daily) and course (4 to 8 weeks, then a break); read November 4, 2026. https://www.defymedical.com/blog/what-is-the-wolverine-peptide-stack/
  12. Patrick Taylor, MD (Live Vital). BPC-157. Cited for its published dose (250 to 500 mcg a day), frequency and 4 to 12 week cycles; read November 4, 2026. https://www.drpattaylor.com/peptides/bpc-157
  13. VitalRx. BPC-157 peptide therapy. Cited for its published dose (250 to 500 mcg per injection, once or twice daily) and 500 mcg oral capsules; read November 4, 2026. https://vitalrx.io/peptide-therapy/bpc-157
  14. Dr. Rogers Centers. BPC-157 dosage: a complete guide. Cited for its own published dose and course; read November 4, 2026. https://drrogerscenters.com/blogs/news/bpc-157-dosage-a-complete-guide
  15. Optimize 360. BPC-157. Cited for its own published dose and course; read November 4, 2026. https://www.optimize360now.com/medications/bpc-157/
  16. Pramah / The Haven, Tampa. BPC-157. Cited for its own published dose, route and course; read November 4, 2026. https://pramahtampa.com/bpc-157/
  17. Perfect B. BPC-157 dosage protocol. Cited for its own published dose and course; read November 4, 2026. https://www.perfectb.com/bpc-157-dosage-protocol/
  18. Institute for Healthy Aging (AMT Care). Peptide therapy. Cited for its own published dose and course; read November 4, 2026. https://www.amtcare.com/treatments/peptide-therapy.html
  19. Beyond Stem Cells. Best way to take BPC-157: the complete guide to dosing and administration. Cited for its own published dose and course; read November 4, 2026. https://beyondstemcells.com/best-way-to-take-bpc-157-the-complete-guide-to-dosing-and-administration/
  20. Yunique Medical. BPC-157 dosage. Cited for its own published injection and oral doses and course; read November 4, 2026. https://yuniquemedical.com/bpc-157-dosage/
  21. Wittmer Rejuvenation Clinic. BPC-157 capsules treatment plan. Cited for its own published oral dose and course; read November 4, 2026. https://wittmerrejuvenationclinic.com/bpc-157-capsules-treatment-plan-how-to-take-bpc-157-capsules/
  22. Salzman S, Kekatos M. FDA advisory committee votes to add popular peptide BPC-157 to compounding list. ABC News, July 23, 2026 (read November 12, 2026): the 8 to 6 vote with one abstention. https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated